1. Medtech Insight
  2. >>Policy & Regulation

CMS Redefines Coverage-With-Evidence-Development In Draft Guidance

The document replaces a 2006 guidance, making substantial changes in response to public comment and six years of experience with the policy. The policy allows for national Medicare coverage under the condition that data be collected on use of the item or service in Medicare beneficiaries.

CMS took steps to further refine its coverage-with-evidence-development (CED) policy with release of a new draft guidance Nov. 29.

The document replaces a 2006 guidance, making substantial changes based on public comments and six years of experience with the program, in which national coverage is provided on the condition that data be collected on use of the item or service in Medicare beneficiaries

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

How Structured Patient Engagement Gives Medtech Companies A Competitive Edge

 
• By Amanda Maxwell

Communication with patients has become a particularly crucial factor for investors, payers, and other healthcare decision-makers in a hostile market environment.